Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 7kWORD 28k
1 April 2016
Answer given by Mr Andriukaitis on behalf of the Commission
Question reference: E-001273/2016

The Commission supports research and innovation on the causes, prevention, early diagnosis and treatment of epilepsy. Under the 7th EU Framework Programme for Research(1), support to epilepsy research amounted to more than EUR 115 million, with EUR 45 million(2) specifically dedicated to projects on new biomarkers for better diagnosis, refined therapies and better understanding epilepsy causes.

The first calls of Horizon 2020(3), the EU Research and Innovation Programme, offered many possibilities for research on epilepsy, resulting in an additional commitment to epilepsy research of more than EUR 24 million for 21 research projects. This includes projects on the development of new therapies and validation of devices for the remote monitoring of epileptic patients.

In addition, the 3rd call for proposals of the Innovative Medicine Initiative 2(4), currently under evaluation, called for developing predictive tools for non-invasive remote monitoring of epilepsy. Horizon 2020 may provide further opportunities for research and innovation in the field of epilepsy, notably from the societal challenge ‘Health, demographic change and well-being’(5).

To support Member States in their efforts to improve epilepsy care, the Commission is supporting with funds made available by the European Parliament, a European study on the burden and care of epilepsy(6) to facilitate the development of high-quality epilepsy care on an equitable basis across EU countries.

(2)HEALTH.2013.2.2.1-4: Pathophysiology and therapy of epilepsy and epileptiform disorders; http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/fp7/calls/fp7-health-2013-innovation-1.html
(3)The EU Framework Programme for Research and Innovation (2014-2020).

Legal notice